GHAM
BHVN

Gilman Hill Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Gilman Hill Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,500
Closed -$207K – 228
2021
Q4 		$207K Hold
1,500
– – 0.05% 212
2021
Q3 		$208K Buy
+1,500
New +$187K 0.05% 194

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Gilman Hill Asset Management's BHVN Position: Q1 2022 in Review

Gilman Hill Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 1,500 shares — an estimated $207K sold.

Gilman Hill Asset Management first reported a position in BHVN in Q3 2021 and held it in 2 quarters. The position peaked at $208K in Q3 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

  • Gilman Hill Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
  • Gilman Hill Asset Management sold 1,500 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $207K.
  • Gilman Hill Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 2 quarters.
  • Gilman Hill Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $208K in Q3 2021.
  • 307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on Gilman Hill Asset Management's 13F filing for Q1 2022, filed 14 Apr 2022.